Faculty

Andrew Lee MD PhD is an Associate Professor at Peking University Shenzhen Graduate School and is the Deputy Director of the SMART Hong Kong – Macau – Guangdong Greater Bay Area (GBA) International Clinical Trial Center. He also holds a joint appointment in the Institute of Cancer Research, Shenzhen Bay Laboratory. Andrew received his B.S. from Yale University, and his MD and PhD degrees from Stanford University. He completed his medical residency at Stanford Hospital in the Department of Clinical Pathology, where he focused on clinical manufacturing of cell / gene therapies for first in human clinical trials.

Andrew's research interests focus on advancing cell and gene therapies into first in human clinical trials. He has published over 60 manuscripts on clinical applications of new cell / gene therapy modalities, and contributed to the first US FDA IND approval for a pluripotent cell therapy product. Andrew's research has published in Cell, Nature Medicine, Nature Biotechnology, Nature Biomedical Engineering, JAMA, and Circulation. According to Google Scholar, he has been cited over 11,000 times with an H-index of 50. Andrew's research has received support from the American Heart Association, Howard Hughes Medical Institute, and several of the global top 10 pharma companies.

1. Tian Y, Liu Y, Tong Y, Huntoon K, Yang L, Shi J, Estania AP, You Y, Kwak KJ, Hsu WH, Wang Y, Cao J, Dong S, Ma Y, Zhang H, Sun M, Grippin AS, Wu A, Edwards JL, Lu WJ, Lee LJ, Bahrani E, Zhang H, Yang Z, Bai L, Nguyen PK, Jiang W, Lan F^#, Kim BYS^#, Lee AS^#. Skeletal Muscle-Targeted Non-Viral Delivery of Full Length Dystrophin mRNA for Duchenne Muscular Dystrophy. Nature Biomedical Engineering 2026; Accepted for publication. # = senior corresponding author. Impact Factor = 29.23.

2. Yan Y, You Y, Ma S, Yi H, Chen G, Ni J, Ke W, Li L, Bai R, Ran Y, Lu W, Zhu M, Zhang Y, Dai J, Lan F, Lee AS^#, Zhang R^#, Liu X^#, and Chen Z^#. Efficient Scaling up EV-AAV Production via Cellular Nanoporation for Familial Hypercholesterolemia Therapy. Journal of Extracellular Vesicles 2025; 14(11), e70186. # = co-corresponding author. Impact Factor = 14.5

3. You Y, Tian Y, Guo R, Shi J, Kwak KJ, Tong Y, Estania AP, Hsu WH, Liu Y, Hu S, Cao J, Yang L, Bai R, Huang P, Lee LJ, Jiang W, Kim BYS, Ma S, Liu X, Shen Z*, Lan F^#, Nguyen PKN^#, Lee AS^#. Extracellular vesicle-mediated VEGF-A mRNA delivery rescuyes ischaemic injury with low immunogenicity, European Heart Journal 2025; 46(17):1662-1676. # = senior corresponding author. Impact Factor = 38.1

4. Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang C, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CYF, Shan YS, Lee AS^#, L James Lee^#. Dual targeted extracellular vesicles regulate oncogenic genes in advances pancreatic cancer. Nature Communications 2023;14(1):6692. # = co-corresponding author. Impact Factor = 17.69

5. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F^#, Kim BYS^#, Lee AS^#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023:1-14. # = senior corresponding author. Impact Factor = 29.23